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Abstract
Background: Despite the availability of specific vaccines and antiviral drugs, influenza continues to impose a heavy toll on
human health worldwide. Passive transfer of specific antibody (Ab) may provide a useful means of preventing or treating
disease in unvaccinated individuals or those failing to adequately seroconvert, especially now that resistance to antiviral
drugs is on the rise. However, preparation of appropriate Ab in large scale, quickly and on a yearly basis is viewed as a
significant logistical hurdle for this approach to control seasonal influenza.
Methodology/Principal Findings: In this study, bovine colostrum, which contains approximately 500 g of IgG per milking
per animal, has been investigated as a source of polyclonal antibody for delivery to the respiratory tract. IgG and F(ab’)2
were purified from the hyperimmune colostrum of cows vaccinated with influenza A/Puerto Rico/8/34 (PR8) vaccine and
were shown to have high hemagglutination-inhibitory and virus-neutralizing titers. In BALB/c mice, a single administration
of either IgG or F(ab’)2 could prevent the establishment of infection with a sublethal dose of PR8 virus when given as early
as 7 days prior to exposure to virus. Pre-treated mice also survived an otherwise lethal dose of virus, the IgG- but not the
F(ab’)2-treated mice showing no weight loss. Successful reduction of established infection with this highly virulent virus was
also observed with a single treatment 24 hr after virus exposure.
Conclusions/Significance: These data suggest that a novel and commercially-scalable technique for preparing Ab from
hyperimmune bovine colostrum could allow production of a valuable substitute for antiviral drugs to control influenza with
the advantage of eliminating the need for daily administration.
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Introduction
Influenza is a highly contagious acute respiratory disease.
Seasonal epidemics can affect 5–15% of the population, leading to
an estimated 3–5 million cases of severe illness and an average of
250,000–500,000 deaths annually (www.who.int). Infection is
mainly confined to the upper respiratory tract and large airways
and only on rare occasions is primary viral pneumonia observed.
The infection usually lasts for about 7–10 days and is
characterized by the sudden onset of high fever, myalgia,
headache and severe malaise, non-productive cough, sore throat,
and rhinitis. Most people recover within one to two weeks without
requiring any medical treatment but the economic impact of
related factors such as time off work is significant. In the elderly,
young children or those with certain underlying medical
conditions, severe complications such as pneumonia due to
secondary bacterial infection can accompany influenza and pose
a serious threat. Typically, influenza virus is transmitted from
infected individuals through aerosols produced by coughing and
sneezing or through contact with contaminated surfaces. Symp-
toms can appear as soon as a day after exposure.
Prevention of influenza virus infection through vaccination
poses a significant challenge. The high mutation rate that occurs
during replication of the virus and selection of neutralisation-
escape variants by pre-existing antibodies, leads to the virus
undergoing ‘‘antigenic drift’’ within populations, such that a
particular influenza vaccine usually confers protection for only a
few years. For this reason, the strain composition of the vaccine
needs to be updated regularly, often with virus isolates circulating
in the previous winter in the opposite hemisphere. The vaccine is
formulated each season with two influenza type A strains and a
type B strain that are predicted to be antigenically well matched
with influenza virus strains that are expected for the coming
influenza season. However, the need to vaccinate yearly is one
contributing factor to poor uptake rates and, even if vaccinated, it
is possible to fall ill; the vaccine is only about 70% efficacious in
young healthy adults [1] and on occasion the chosen vaccine strain
does not match the emerging virus making it significantly less
effective [2]. Vaccination against influenza does remain an
important preventative health measure for the elderly where it
can provide a 60% reduction in morbidity and 70–80% reduction
in influenza-related mortality (www.who.int).
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antiviral drugs are available. The adamantanes [3], amantadine
and rimantadine, are inhibitors of the M2 ion channel and
interfere with viral uncoating inside the cell. Though relatively
inexpensive, their use has been associated with toxicity and the
rapid emergence of drug-resistant variants [4], which are already
prevalent worldwide amongst seasonal strains [5,6] as well as the
recently emerged swine origin pandemic virus [7]. Inhibitors of the
viral neuraminidase, oseltamivir and zanamivir [8] stop the
efficient release of progeny virus from infected host cells, thus
reducing cell-to-cell spread. Neuraminidase inhibitors initially
appeared less likely to promote drug-resistance but oseltamivir-
resistant virus has arisen after treatment of patients [9,10] and are
now widespread in circulating strains [11,12] To be effective, the
time of commencement of treatment with anti-influenza drugs
must be within two days of illness onset and the treatment is
ongoing throughout the infection [13].
Despite these measures, annual epidemics continue to cause
substantial morbidity and mortality worldwide and additional
control strategies to compliment existing methods would be of
significant benefit. What we currently lack is a method of
prevention or treatment that provides no risk of selection of
resistant strains and does not rely on continuous administration.
Passive immunotherapy may provide a suitable option to fill this
niche. Patients with diseases as diverse as rabies, hepatitis and
respiratory syncytial virus (RSV) have been successfully treated
with antibody (Ab) derived from hyperimmune sera from human
or other animal origin [14]. Passive Ab therapy has also been
shown to provide prophylaxis for high-risk individuals. In animal
models of influenza, anti-viral polyclonal antisera from a variety of
species have been successful in treating and preventing infection
[15,16] showing proof-of-principle for this disease.
Monoclonal antibodies (MAbs) targeting the viral hemaggluti-
nin (HA) have been actively pursued as a continuous source of
highly specific neutralising Ab [17,18]. However, individual MAbs
only target a single epitope on the virus so cocktails of MAbs with
different specificities need to be used in order not to drive drift of
the virus and this becomes very costly. Redeveloping such reagents
every few years would be prohibitive. A technique to mass-
produce polyclonal Abs at a low cost has been developed by
Immuron Ltd. The polyclonal Abs are from vaccinated cattle and
derived from the colostrum, the first milk given by the cow after
birth. Using this dairy harvesting system, large amounts of Ab-rich
product can be economically derived with yields of about 500 g of
polyclonal IgG per vaccinated animal. We report here on the
prophylactic and therapeutic efficacy of hyperimmune colostrum-
derived antibodies against influenza virus in a mouse model.
Materials and Methods
Ethics statement
All experimental procedures using mice were carried out using
protocols approved by the Animal Ethics Committee of the
University of Melbourne (project 0703485.1). Vaccination of cows
was done with approval of the Immuron Animal Ethics
Committee, convened and registered under Victorian law (projects
A04 and A09).
Preparation of colostrum samples
First milking colostrum was collected from cows following
immunization with three doses, 2 weeks apart, of purified
detergent-disrupted A/Puerto Rico/8/34 (PR8) influenza virus
in a water-in-oil emulsion adjuvant (Seppic, Fairfield NJ, USA).
First milking colostrum was also collected from non-immunized
cows for use as a control. Colostrum samples were centrifuged at
10,0006 g for 30 mins at 4uC to remove fat and cells. Defatted
colostrum was pasteurized 63.5uC for 30 mins and then
recentrifuged. Colostrum whey was prepared by adjusting the
pH to 4.6 with an equal volume of 0.2M sodium acetate solution
(pH 4.0) while mixing at 37uC. The liquid was then left at 37uC
for 2 hr, cooled and centrifuged at 10,0006 g for 30 mins to
remove casein.
Purification of F(ab’)2 fragments
Part of the colostral whey was adjusted to pH 4.0 and incubated
with pepsin for 20 hrs at 37uC using a modification of the method
by Jones and Landon [19]. Increasing the pH to 7.0 stopped
pepsin digestion. The digested material was then centrifuged at
10,0006 g (4–12uC) to remove the precipitate. Tangential flow
diafiltration was then performed using a 30,000 MW cut-off
membrane to remove low molecular weight products and washed
with diafiltration buffer (20 mM sodium phosphate, 150 mM
NaCl, pH 6.0). The filtrated product was then passed through a
Q-Sepharose column to remove pepsin and residual acidic
aggregates. All unbound material which corresponds to F(ab’)2
fragments was collected and stored at 4uC. The final product was
diluted in PBS. Protein concentration was determined by
measurement of absorbance at 280 nm with a spectrophotometer.
Purification of IgG
Another part of the colostral whey was adjusted to pH 6.6 and
then diafiltrated against phosphate buffered saline (PBS: 20 mM
sodium phosphate, 150 mM NaCl pH 7.5). This whey was filtered
to 0.45 mm prior to purification using Protein-G Sepharose
chromatography, using PBS as running buffer and 50 mM citrate
pH 2.6 as elution buffer. After elution, peak protein was
neutralized with 1M Tris pH 8.0 and then diafiltrated against
PBS.
Polyacrylamide gel electrophoresis (PAGE)
One microgram of protein in sodium dodecyl sulfate (SDS)
sample buffer was subjected to electrophoresis under reducing and
non-reducing conditions in a 4–20% Tris-HEPES SDS-PAGE gel.
Protein bands were detected with Coomassie blue G-250 staining.
Hemagglutination inhibition (HI) assay
HI assays were performed by standard procedures [20] in
round-bottom polystyrene microtitre plates (Nunc, Denmark)
using 1% chicken red blood cells. Titers are expressed as the
reciprocal of the highest dilution of sample that inhibited 4
hemagglutinating units (HAU) of virus.
Virus neutralization (VN) assay
The assay utilises virus plaque formation in Madin-Darby
canine kidney (MDCK) cells [21]. Monolayers of MDCK cells
were prepared by seeding 1.2610
6 cells in 3 ml of RPMI medium
containing 10% fetal calf serum in each well of the tissue culture 6-
well plate (TPP, CSL Ltd) and incubating overnight at 37uCi n5 %
CO2. The monolayers were then washed with medium containing
antibiotics before adding 135 ml of virus-Ab mixtures to each well,
in duplicate. The virus-Ab mixtures comprised half-log serial
dilutions of Ab in 200 ml mixed with an equal volume of influenza
virus to provide a final concentration of about 200 plaque forming
units/135 ml and incubated together for 30 min at 37uC. The
mixtures were allowed to adsorb to the monolayers for 45 min,
with shaking of the plates at 15 min intervals. Then 3 ml warmed
(45uC) overlay medium consisting of Leibovitz L-15 with
Colostrum Abs for Influenza
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Australia) supplemented with 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid buffer (0.01M at pH6.8), 0.028% (w/v) NaHCO3
(APS Finechem, NSW, Australia), 100 IU per ml penicillin (CSL
Ltd), 100 mg per ml streptomycin (CSL Ltd), 0.1% (w/v) TPCK-
treated trypsin (Worthington Biochemical Corp., Lakewood, NJ,
USA) and 0.9% (w/v) agarose (Sigma Chemicals Co.) were added
to each well. The plates were then incubated at 37uCi n5 %C O 2
for 3 days. Plaques on the monolayers were then counted without
staining. The VN titer was expressed as the reciprocal of the
highest dilution that reduced the number of plaques to 50% of the
control value in the absence of Ab.
Mice and influenza virus infection
Inbred 6- to 10- week BALB/c mice (H-2d) were bred and
housed at the Animal Facility of the Department of Microbiology
and Immunology at the University of Melbourne. Mice were
infected with 50 pfu (sublethal dose) or 500 pfu (lethal dose) of
influenza A/Puerto Rico/8/34 (PR8, H1N1) by the intranasal
(i.n.) route, either to the upper or total respiratory tract. In the
upper respiratory tract (URT) model, inoculum is given to the
nares of unanaesthetized mice in a small volume (10 ml), which
confines the inoculum to the nasal turbinates. For the total
respiratory tract (TRT) model, 50 ml of inoculum is given to the
nares of the mice under penthrane anesthesia.
Activity of Ab in vivo
In the prophylaxis experiments, anesthetized mice were given
50 ml of the Ab preparations or PBS intranasally (i.n.) 1, 2, 3 or 7
days before PR8 virus infection. For the localized treatment of the
upper respiratory tract, unanaesthetized mice were given 10 mlA b
preparations i.n. on day 1 or on days 1 and 3 post URT infection.
For treatment of the entire respiratory tract, anesthetized mice
were given 50 ml Ab on days 1 or 2 post TRT infection. Mice were
killed by cervical dislocation, one day (for prophylaxis experi-
ments) or 5 days (for treatment experiments) after infection with a
sublethal dose of virus. Nasal turbinates (in URT infected mice) or
lungs (in TRT infected mice) were removed and homogenized and
infectious viral titres were determined by plaque assay. For the
survival experiments, mice infected with a lethal dose of virus were
culled if they had lost .20% of their starting body weight and
additionally displayed clinical signs of illness such as inactivity or
hunched appearance.
Detection of bovine IgG in tissue homogenates and sera
Anesthetized mice were given 50 ml of the anti-PR8 Ab
preparation intranasally. After various intervals (1, 12, 24 and
36 hr), mice were killed and nasal turbinates, lungs and sera were
collected. The tissues were homogenised in 1 ml of RPMI and
both supernatants and sera were tested by ELISA for the presence
of bovine Ab using a Bovine IgG ELISA quantitation set from
Bethyl Laboratories, Montgomery, Texas, USA.
Statistical analyses
These were carried out using the software package Prism
(v.4.0c) from GraphPad Software Inc. A one-way ANOVA test
with 95% confidence interval was employed. P values were
obtained by using a Tukey post-test.
Results
Characterization of colostrum-derived IgG and F(ab’)2
preparations
The IgG and F(ab’)2 preparations, derived from PR8-immune
and non-immune colostrum samples, were subjected to SDS-
PAGE (Fig. 1). Under non-reducing conditions, the IgG
Figure 1. SDS-PAGE of IgG and F(ab’)2 preparations. Protein samples in SDS buffer were subjected to electrophoresis under non-reducing and
reducing conditions through a 4–20% Tris-HEPES SDS-PAGE gel. The gel was stained with Coomassie blue G-250. Molecular mass markers (M) are
indicated in kilodaltons. NI, non-immune. The minor band in the non-immune IgG preparation run under non-reducing conditions corresponds to IgG
dimers which can sometimes form after freeze-drying. The results are typical of profiles from three separate SDS-PAGE analyses of these particular
preparations and of many other analyses of colostrum-derived antibodies .
doi:10.1371/journal.pone.0013622.g001
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molecular mass of 160 kDa, while the F(ab’)2 preparations
migrated as a major band of 110 kDa, corresponding to F(ab’)2
and a minor band at 55 kDa corresponding to F(ab’), present due
to over-digestion with pepsin. Under reducing conditions, the IgG
preparations migrated as two protein bands corresponding to the
heavy chain (MW of 50 kDa) and light chain (25 kDa) while
F(ab’)2 migrated as a single band at 25 kDa.
The activity of the purified IgG and F(ab’)2 preparations was
tested in hemagglutination inhibition (HI) and virus neutralization
(VN) assays against PR8 virus in vitro. Table 1 shows that the
immune preparations both had high HI and NV titers whereas the
non-immune control preparations showed no detectable activity in
either assay.
Therapeutic efficacy of anti-PR8 IgG and F(ab’)2 in the
URT
The effect of the purified preparations on influenza virus in vivo
was examined using a mouse model. Firstly, we performed a dose
titration of the Ab preparations by treating mice with 50 mg,
100 mg, 150 mg or 200 mg of anti-PR8 IgG, anti-PR8 F(ab’)2, non-
immune control Abs or PBS via the URT route, 24 hrs after
establishment of infection with PR8 virus. Nasal turbinate viral
titres were determined 5 days post-infection (4 days post-
treatment) when normally still at their peak in untreated animals.
As shown in Figure 2A, 200 mg of the immune IgG preparation
resulted in a 100-fold reduction in viral titers compared to the
PBS-treated mice (p,0.001). Lower doses showed no statistically
significant differences compared to the PBS group. The immune
F(ab’)2 preparation did not show any reduction in viral loads at
any of the doses tested (Fig. 2B).
A limitation of the URT route model is that only a small volume
can be administered, prohibiting treatment with larger doses of Ab
at any one time. Therefore, we investigated whether multiple
administrations would further aid in the suppression of viral
replication. On days 1 and 3 post PR8 virus infection, mice were
treated with 200 mg of immune IgG, immune F(ab’)2, or non-
immune control preparations or PBS via the URT route. Figure 3
shows that the viral titres in the immune IgG-treated animals were
significantly lower than their control counterparts 5 days post-
infection. However, the dose response pattern was essentially no
different from a single dose treatment regime. Furthermore, two
doses of anti-PR8 F(ab’)2 was still insufficient to reduce viral titres
in the nasal turbinates.
Therapeutic activity of anti-PR8 IgG and F(ab’)2 in the TRT
We took a similar approach to investigating the ability of
different concentrations of Ab to clear virus from the lungs of
infected mice after TRT delivery. As with the URT model, the
non-immune IgG and F(ab’)2 preparations delivered by the TRT
route 24 hrs after virus infection provided no reduction of viral
loads in the lungs (Fig. 4A and B). However, 100% of mice treated
with 1 mg of anti-PR8 IgG had undetectable viral titers in the
lungs 5 days later (Fig. 4A). Half of the mice treated with 500 mg
and 800 mg of anti-PR8 IgG completely cleared lung virus and the
remainder showed partial clearance, with the mean viral titers of
these groups significantly lower than the PBS control mice
Table 1. Hemagglutination inhibition and virus neutralization
titers of Ab preparations.
Antibody
preparation
a HI titer VN titer
Anti-PR8 IgG 1280
b 80,000
Anti-PR8 F(ab’)2 2560 400,000
Non-immune IgG ,10 ,10
Non-immune F(ab’)2 ,10 ,10
aAntibody preparations were tested from a starting concentration of 20 mg IgG
or F(ab’)2 per ml.
bMean of four determinations, each giving identical results.
doi:10.1371/journal.pone.0013622.t001
Figure 2. Virus loads are reduced in the nasal turbinates after
treatment with the anti-PR8 IgG preparation. Unanesthetised
BALB/c mice (n=4) were given 500 pfu of PR8 virus in 10 ml by the
intranasal route to establish a localised URT infection. Twenty four
hours post-infection, mice were treated with 200 mg, 150 mg, 100 mgo r
50 mg of (A) anti-PR8 IgG or non-immune IgG or (B) anti-PR8 F(ab’)2 or
non-immune F(ab’)2 or PBS via the URT route. Five days post-infection,
mice were killed and nasal turbinates were collected in 1 ml media. Viral
titers were determined by plaque assay on MDCK cell monolayers. The
experiment was performed once with 4 mice per group, the organs
assayed in quadruplicate and titers averaged to provide a value for that
animal. Each symbol represents an individual mouse and the line
represents the mean of each group. The bracket with an asterisk
indicates a statistically significant difference between the indicated
groups.
doi:10.1371/journal.pone.0013622.g002
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concentrations of immune IgG (100 mg and 200 mg), no significant
decreases in lung viral titres were observed. Treatment with
equivalent amounts of anti-PR8 F(ab’)2 did not provide complete
clearance at any of the doses tested (Fig. 4B). Nevertheless,
significant partial clearance was observed, particularly at the
highest dose where 100-fold less virus was present in the lungs on
day 5 (p,0.001), and also at 800, 500 and 200 mg doses (p,0.05
for all three).
Of interest was whether the decreased pulmonary viral loads
seen 5 days after virus infection in mice treated with 1 mg of the
immune F(ab’)2 preparation might enable the mouse’s own
developing immune system to clear the virus more rapidly.
Typically, this sublethal dose of PR8 will not be completely cleared
in untreated animals until day 10 post infection. As shown in
Figure 4C, by day 7 post-infection, lung viral titres in anti-PR8
F(ab’)2-treated mice have decreased over 1000-fold compared to
non-immune F(ab’)2-treated mice, with 1 mouse showing unde-
tectable viral titres. This implies an increase in the rate of overall
viral clearance of 2–3 days after a single dose of immune F(ab’)2.
Treatment with the immune antibody preparations on day 2
post infection gave somewhat less of an effect (Fig. 5). Nevertheless,
a reduction in viral titres was seen in the anti-PR8 IgG treated
mice (mean 50-fold reduction, p,0.05) and also in the F(ab’)2-
treated mice (mean 10-fold reduction), although the latter was not
statistically significant by the ANOVA test used.
Prophylactic efficacy of anti-PR8 IgG and F(ab’)2 in the
total RT
The activity of the Ab preparations was then investigated in a
prophylactic setting (Fig. 6). Anti-PR8 IgG, anti-PR8 F(ab’)2, non-
immune Ab or PBS were given via the TRT route 1, 2, 3 or 7 days
prior to infection with a non-lethal dose of PR8 virus. One day
later the lungs of the mice were examined for infectious virus.
Anti-PR8 IgG given as early as 3 days prior to infection completely
inhibited virus growth in the lungs. This was also true for 4 of 5
mice given the immune IgG seven days prior to viral infection,
with the remaining animal showing very low titers, less than 1/
100
th of the PBS controls. Anti-PR8 F(ab’)2 also completely
prevented viral growth when given up to 3 days before infection.
However, anti-PR8 F(ab’)2 was not as efficient in preventing
infection compared to anti-PR8 IgG when given 7 days prior to
infection. Nonetheless, anti-PR8 F(ab’)2-treated mice showed
lower viral titres than PBS control mice.
Of particular interest was the observation that non-immune IgG
(but not non-immune F(ab’)2) was also able to lessen viral loads in
the lungs, by approximately 10-fold if delivered one (P,0.05) or 2
(p,0.01) days prior to infection.
Ability of colostrum derived Abs to counter lethal
infection
After successful demonstration of the ability of the immune
colostrum preparations to reduce or inhibit infection with a sub-
lethal dose of influenza virus in vivo, we went on to assess their
ability to counter infection with a lethal dose of PR8 virus. Anti-
PR8 IgG, F(ab’)2, the non-immune counterparts or PBS were
given before (Fig. 7) or after (Fig. 8) PR8 infection and the mice
monitored over a period of 16 days post infection for weight loss.
Where necessary, mice were culled at the pre-determined humane
endpoint. When the Ab preparations were given 3 days before
infection (Fig. 7A and C), anti-PR8 IgG or F(ab’)2-treated mice not
only survived but maintained their bodyweights. Non-immune
IgG-treated mice initially lost substantial weight but otherwise did
not show signs of severe infection; all but one mouse (that was
culled) eventually regained weight. In contrast, non-immune
F(ab’)2 and PBS treated mice rapidly lost weight, showed clinical
signs of severe infection and had to be culled by day 7.
When the Ab preparations were administered 7 days before
infection (Fig. 7B and D), all groups of mice, except the group
treated with anti-PR8 IgG, lost weight. The average rate of weight
loss in the anti-PR8 F(ab’)2-treated mice was slower, however, and
3 of the 5 mice continued to be active and eventually regained
weight; the other two were culled on days 10 and 11. Mice treated
with non-immune preparations behaved similarly to PBS control
mice, rapidly losing weight and becoming inactive prior to culling
on days 6–8.
Treatment with a single dose of anti-PR8 IgG or F(ab’)2 24 hr
after lethal infection (Fig. 8) completely prevented weight loss,
severe disease and death. Mice that were given non-immune Ab or
PBS rapidly lost weight over a period of 6 days, displayed severe
clinical signs and had to be killed between days 5 and 7 post-
infection.
Bovine IgG is retained for long periods in the lungs of
mice
The ability of the anti-PR8 IgG preparation to prevent weight
loss and death when given 7 days prior to lethal infection suggested
that the Ab either remained within the RT for long periods or
entered the bloodstream and was recruited back into the RT upon
inflammation due to viral infection. To investigate the persistence
of bovine Ab, mice were anesthetized and given 1 mg anti-PR8
IgG preparation in 50 ml i.n. After 1, 12, 24 and 36 hr, mice were
killed and supernatants of homogenised nasal turbinates and lungs
as well as sera were assayed in a capture ELISA for the presence of
Figure 3. Virus load reduction is not enhanced by a second
dosing with Ab. BALB/c mice were given 500 pfu of PR8 virus in 10 ml
by the intranasal route to establish a localised URT infection. One and 3
days post-infection, mice were treated with 200 mgo fe a c hA b
preparation or PBS via the URT route. Five days post-infection, mice
were killed and nasal turbinates were collected in 1 mL media. Viral
titers were determined by plaque assay on MDCK cell monolayers. The
experiment was performed once with 4 mice per group, the organs
assayed in quadruplicate and titers averaged to provide a value for that
animal. Each symbol represents an individual mouse and the line
represents the mean of each group. Brackets with an asterisk indicate a
statistically significant difference between the indicated groups.
doi:10.1371/journal.pone.0013622.g003
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IgG does make its way into the bloodstream, peaking sometime
between 1 to 12 hr but then is cleared with a half-life of about
15 hr. High levels in the nose are not maintained and are rapidly
cleared with a half-life of about 4 hr. In contrast, bovine IgG
persists in the lungs at high levels with a calculated half life of at
least 36 hr.
Discussion
For this study, highly active preparations of IgG and F(ab’)2
containing polyclonal antibody with specificity for influenza virus
PR8 were prepared from the colostrum of vaccinated cows. To
our knowledge, few studies have demonstrated the effects of
hyperimmune polyclonal antibody for prevention and treatment of
influenza infection when given via the intranasal route [22]. When
tested in mice with established PR8 infection of the nose, we
showed that 200 mg of the IgG preparation could lead to
significant reduction of infectious virus at that site. Similar effects
in humans would imply a reduced rate of shedding and potential
decrease in transmission, providing a community as well as a
personal benefit. At the doses tested, however, the anti-PR8 F(ab’)2
showed no such effect on URT infection despite this preparation
having similar anti-viral titres in vitro. This may have been due to
Figure 4. Virus loads are reduced in the lungs after treatment with the anti-PR8 IgG and F(ab’)2 preparations. BALB/c mice (n=4) were
infected with 50 pfu of PR8 virus in 50 ml via the TRT route under penthrane anaesthesia. Twenty four hours post-infection, mice were treated with
1000 mg, 800 mg, 500 mg, 200 mg or 100 mg of (A) anti-PR8 IgG or non-immune IgG or (B) anti-PR8 F(ab’)2 or non-immune F(ab’)2 or PBS via TRT route.
Five days post-infection, mice were killed and lungs were collected in 1 ml media. (C) Mice were infected and treated as in (B) and lungs sampled 7
days post infection. Viral titres were determined by plaque assay on MDCK cell monolayers. The experiment was carried out in its entirety once and
results are consistent with repeat experiments on selected doses. Each symbol represents an individual mouse and the line represents the mean of
each group. Brackets with an asterisk indicate a statistically significant difference (p,0.001) between the indicated groups.
doi:10.1371/journal.pone.0013622.g004
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dependent cellular cytotoxicity or Ab plus complement lysis of
infected cells, but may equally be a function of the slightly
increased longevity of intact IgG (36over Fab) in the respiratory
tract [25]. Treatment with a second dose of Ab two days later did
nothing to improve the reduction in viral loads mediated by IgG.
This may suggest that once the virus loads are set early in infection
by the first dose of antibody, the impact of a second dose of
antibody later on is minimal compared to the viral clearance
mediated by the developing immune response.
Treatment of the entire respiratory tract with 1 mg of anti-PR8
IgG given 24 hr after a sub-lethal infection resulted in total
clearance of virus from the lungs measured on day 5 after
infection. If treatment was delayed for a further 24 hrs, somewhat
less impressive but nevertheless significant clearance levels (100-
fold) were achieved. An effect on viral loads was also seen with the
anti-PR8 F(ab’)2 preparation, possibly because of the greater doses
that could be tested via this route of delivery compared to URT
delivery. The reduction in viral loads after treatment with F(ab’)2
resulted in mice being able to clear the virus about 2–3 days earlier
than untreated mice. In this respect, treatment with only a single
dose of F(ab’)2 gave similar benefits to continued administration of
anti-viral drugs [13]. Importantly, treatment with 1 mg of either
anti-PR8 IgG or F(ab’)2 24 hr after a lethal dose of PR8 not only
prevented death of all animals but also prevented development of
severe disease with minimal weight loss.
Testing of the antibody preparations for their prophylactic
effects revealed that a single dose of anti-PR8 IgG, given up to 7
days before PR8 infection, was able to completely prevent the
establishment of pulmonary infection in mice challenged with a
sub-lethal dose of virus, and also completely protect against weight
loss and death following a lethal dose of the virus. The long lasting
effects of the bovine IgG is compatible with its half-life of .36 hr
in the lungs, which contrasts with the shorter half-life observed in
the nasal tissue and serum. Anti-PR8 F(ab’)2 was also able to
completely prevent virus establishment in the lungs and a lethal
outcome but the longevity of this effect after a single dose was not
as great as observed with IgG.
When translated into human use, it is likely that the duration of
the prophylactic effect seen with IgG will be more comparable to
what we have seen here with F(ab’)2. The longevity of bovine IgG
in mice, as seen with day 7 prophylaxes, may be attributed to the
Figure 5. Virus loads are reduced but by a lesser extent if Ab
treatment is delayed. BALB/c mice were infected with 50 pfu of PR8
virus in 50 ml via the TRT route under penthrane anaesthesia. Two days
post-infection, mice were treated with 1 mg of the Ab preparations or
PBS via the TRT route. Five days post-infection, mice were killed and
lungs were collected in 1 ml media. Viral titres were determined by
plaque assay on MDCK cell monolayers. The experiment was performed
once with 5 mice per group, the organs assayed in quadruplicate and
titers averaged to provide a value for that animal. Each symbol
represents an individual mouse and the line represents the mean of
each group. Brackets with an asterisk indicate a statistically significant
difference between the indicated groups.
doi:10.1371/journal.pone.0013622.g005
Figure 6. Anti-PR8 IgG and F(ab’)2 preparations can completely prevent influenza infection. BALB/c mice (n=5) were given 1 mg of the
Ab preparations or PBS via the TRT route in 50 ml under penthrane anaesthesia. One, 2, 3 or 7 days later, mice were infected with 50 pfu of PR8 virus
in 50 ml via the TRT route under penthrane anaesthesia. One day post-infection, mice were killed and lungs were collected in 1 ml media. Viral titres
were determined by plaque assay on MDCK cell monolayers. Each symbol represents an individual mouse and the line represents the mean of each
group. The experiment was carried out in its entirety once and results are consistent with repeat experiments on selected doses.
doi:10.1371/journal.pone.0013622.g006
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IgG from degradation by transporting it within and across cells
[26], although this effect is much less pronounced with IgG
delivered intranasally [25]. Mouse FcRn has been shown to be
highly promiscuous as it binds Fc of different species including
bovine IgG, whereas human FcRn binds less well to IgG from this
species [27]. For systemic application of therapeutic Abs the issue
of longevity is important for reducing the number of doses
required but is also a double-edged sword. The host will eventually
develop an immune response against the Fc portion of an
administered whole Ab of a different species, causing hypersen-
sitivity reaction [28,29]. Development of effective F(ab’)2 for
prophylaxis and treatment has therefore become increasingly
important and delivery of this product by the intranasal route
rather than systemically may provide additional safety.
In the prophylaxis experiment, a surprising observation was that
non-immune IgG, but not non-immune F(ab’)2, had a short term
role in partially reducing pulmonary viral titres and death, though
not morbidity. This is in contrast to the use of non-immune Ab for
therapy of an established infection where it had no effect.
Although the non-immune IgG showed no HI or VN activity in
vitro, it may contain low levels of Ab that can act upon virions or
infected cells by Fc-dependent mechanisms in vivo. This is
supported by the observation of low levels of binding of the non-
immune IgG to PR8 virus in ELISA (data not shown). The
appearance of such Ab in the colostrum of unvaccinated cows may
indicate cross-reactivity with other antigens encountered by this
host.
The gathering of antibodies from bovine colostrum and their
use in controlled clinical studies for a variety of infectious diseases,
particularly for oral use against gastrointestinal diseases [30], has
shown both prophylactic and therapeutic effects [31]. The
production systems are well known in areas of the dairy industry
and colostrum is produced in tonne volumes for use as a food
supplement in many markets through the world. The techniques
of vaccinating dairy cattle in large numbers in strategic campaigns
is also well known to the veterinary profession and farmers as cattle
are routinely vaccinated against cattle pathogens. An additional
course of killed adjuvanted vaccines targeting a human pathogen
can easily be applied within modern animal husbandry routines
and IgG can be collected with variations of routine dairy
techniques. Colostrum from cattle is very high in IgG as it is the
main route of transfer of the immune proteins to the calf, which
can directly absorb these large proteins to the blood within the first
24 hours [31]. The modern dairy cow produces much more
colostrum that a single calf requires.
Figure 7. Anti-PR8 IgG and F(ab’)2 preparations can prevent severe weight loss and death from a lethal dose of PR8 virus. BALB/c
mice (n=5) were treated with 1 mg of the Ab preparations or PBS in 50 ml i.n. under penthrane anaesthesia. On days 3 (A and C) or 7 (B and D) after
Ab administration, mice were infected with 500 pfu of PR8 virus in 50 ml via the TRT route under penthrane anaesthesia. Mice were monitored daily
for 16 days and killed at the humane endpoint. The experiment was performed once in accordance with animal ethics approvals. The change in
percentage of the starting weight (A and B) and Kaplan-Meier survival curves (C and D) are shown.
doi:10.1371/journal.pone.0013622.g007
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large amounts of specific Ab (estimated as sufficient for at least 500
human doses from each cow) but the antibody is polyclonal and
can easily be converted to IgG and F(ab’)2. This study builds on
previous observations on the use of F(ab’)2 to successfully treat
influenza infection [16], even in severe combined immunodefi-
ciency (SCID) mice [18,25]. The F(ab’)2 used in those studies,
however, was derived from a MAb preparation. With all Ab being
of the desired specificity, only a relatively low dose was required to
clear virus. The dose of Ab used in our study is necessarily large as
much of the antibody is non-specific. However the polyclonal Ab
approach has the added advantage of providing broader antigenic
coverage. This should have less effect in driving selection of
resistance and the preparations will be expected to have an
increased lifespan for use against naturally occurring drift variants
due to any neutralizing Ab against epitopes that persist for several
years. Such epitopes cannot be predicted with certainty. Current
strategies using MAbs aim to prepare multi-specific preparations
by combining several MAbs as a ‘cocktail’ [32,33], which may
overcome these hurdles but increases the expense, which is already
high for large-scale production. Human anti-influenza MAbs have
been successfully prepared and tested in mice for use against
H5N1 infection [33] but for mouse-derived MAbs, the additional
step of ‘‘humanizing’’ mouse-derived MAbs to reduce hypersen-
sitivity [32] for parenterally delivered preparations also increases
cost and lead time to product availability. Furthermore, technol-
ogies that rely on delivering Ab preparations with only a small
number of specificities selected prior to or at the beginning of an
epidemic may lose protective capacity during the course of an
epidemic in certain individuals as the virus evolves.
This study shows the potential of bovine colostrum-derived
polyclonal antibodies or their fragments delivered to the
respiratory tract for both treatment and prevention of influenza.
Due to the relative low cost and high volume capability of
production, this new approach represents a significant tool for
individual and large-scale public health management of influenza
in humans. The process, which takes roughly 4 months from first
vaccination of naı ¨ve cows to final product has the potential to be
significantly shortened if the same animals were re-boosted with
the latest strain. This may also select for broadly crossreactive
antibodies which would have a significant advantage if the vaccine
was not a perfect match for the emerging virus, as we see
occasionally with vaccines for human use.
The product would have significant advantages over the use of
antiviral agents due to the lack of need for daily administration and
may be a preferred control measure against drug-resistant viruses.
In those who have suboptimal protection against influenza through
not being previously vaccinated or those vaccinated individuals who
fail to adequately seroconvert, especially the elderly or those with
compromised immune systems, treatment with polyclonal Abs may
have a significant role in reducing morbidity and mortality.
Author Contributions
Conceived and designed the experiments: WCN GR LB. Performed the
experiments: WCN VW. Analyzed the data: WCN LB. Contributed
reagents/materials/analysis tools: VW BM GR. Wrote the paper: WCN
BM GR LB.
Figure 8. Anti-PR8 IgG and F(ab’)2 preparations can prevent
severe weight loss and death from an established lethal PR8
infection. BALB/c mice (n=4) were infected with a lethal dose (500 pfu
in 50 ml) of PR8 virus via the TRT under penthrane anaesthesia. One day
post-infection, mice were treated with 1 mg of the Ab preparations or
PBS in 50 ml via the TRT route. Mice were monitored daily for 16 days
and killed at the humane endpoint. The experiment was performed
once in accordance with animal ethics approvals. The change in
percentage of the starting weight (A) and Kaplan-Meier survival curves
(B) are shown.
doi:10.1371/journal.pone.0013622.g008
Figure 9. Half-lives of intranasally-delivered bovine IgG in the
nose, lungs and serum. The bovine anti-PR8 IgG preparation (1 mg)
was administered in a volume of 50 ml by the i.n. route to anesthetized
mice. At 1, 12, 24 and 36 hr post-administration, mice were killed and
bovine IgG was detected by capture ELISA in nasal turbinate and lung
homogenates and in sera. The total amount of Ab was determined by
reference to a standard curve. Linear regression analysis was used to
calculate the half-lives of bovine IgG in the different sites. The data are
representative of two experiments.
doi:10.1371/journal.pone.0013622.g009
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